SYRE - Spyre Therapeutics Inc.
Spyre Therapeutics Inc. Logo

SYRE - Spyre Therapeutics Inc.

https://www.spyre.com
Hold Momentum: Bearish
Recent News
Powered by Alpha Vantage
Bullish
This Weyerhaeuser Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Sun Communities ( NYSE:SUI ) , Ocular Therapeutix ( NASDAQ:OCUL )
Benzinga • 5 months, 1 week ago • score: 0.33
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Jefferies analyst Peter Abramowitz initiated coverage on Sun Communities, Inc.
AI Tools
Key Metrics
Trend: Downtrend
As of 2025-09-10 (Snapshot)

Spyre Therapeutics, Inc., a biotechnology company, focuses on advancing a pipeline of antibody therapeutics for the treatment of inflammatory bowel disease by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. The company is headquartered in Waltham, Massachusetts.

52W High
$40.26
52W Low
$10.91
MA Status:
50D: Below 200D: Below
Beta (~1 neutral, <0.9 lower risk)
2.88
Valuation
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
-7.96
EV/Revenue (<3 favorable)
1964.91
P/S (TTM) (<3 favorable)
650.22
P/B (<3 favorable)
3.42
Ownership
Institution‑heavy
Source: Overview
Insiders (1–5% typical)
8.71%
Institutions (25–75% balanced)
106.91%
Shares Outstanding
60,401,000
Float
46,735,200
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
0
Gross Profit (TTM)
-176,994,000
EPS (TTM)
-2.53
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
N/A
ROE (TTM) (>15% strong)
-0.50%
EPS YoY (Quarterly) (>10% good)
-1.00
Revenue YoY (Quarterly) (>8% good)
N/A
Momentum
Bearish momentum
Value
0.1607
Previous
0.1476
Trend
Rising
Signal Cross
No cross
As of
Sep. 05, 2025